pyrazines has been researched along with Leukemia in 38 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 19 (50.00) | 29.6817 |
2010's | 18 (47.37) | 24.3611 |
2020's | 1 (2.63) | 2.80 |
Authors | Studies |
---|---|
Chubinskiy-Nadezhdin, V; Morachevskaya, E; Negulyaev, Y; Sudarikova, A; Vasileva, V | 1 |
Bagiński, M; Bieszczad, B; Czajkowska, J; Mieczkowski, A; Mroczkowska, M; Psurski, M; Trzybiński, D; Wietrzyk, J; Wilczek, M; Woźniak, K | 1 |
Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
Gao, L; Shi, J; Tao, Y; Wang, H; Wu, X; Yang, G; Zhan, F | 1 |
Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
Arai, S; Iwakura, Y; Kagoya, Y; Kataoka, K; Kobayashi, H; Kumano, K; Kurokawa, M; Nakagawa, M; Saito, T; Yoshimi, A | 1 |
Anderl, JL; Assaraf, YG; Cloos, J; Jansen, G; Kale, AJ; Kaspers, GJ; Moore, BS; Niewerth, D; Riethoff, LF; van Meerloo, J; Zweegman, S | 1 |
Chudej, J; Chudý, P; Dobrota, D; Hatok, J; Kliková, K; Pilchová, I; Račay, P; Štefaniková, A | 1 |
Amaravadi, RK; Boyiadzis, M; Johnson, DE; Konig, H; Lotze, MT; Sehgal, AR; Tang, D | 1 |
Chen, HX; Wang, XJ; Xu, YH; Yang, GC; Zhang, P | 1 |
Crawford, LJ; Irvine, AE; Walker, B | 1 |
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
Bachmann, AS | 1 |
Li, J; Liu, P; Lu, H; Xu, B | 1 |
Chen, L; Chen, Z; Han, F; Li, J; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H | 1 |
Fuchs, O; Kuzelova, K; Marinov, I; Provaznikova, D; Spicka, I | 1 |
Dewar, MR; Ghaffari, S; Grassian, A; Jagani, Z; Khosravi-Far, R; Kutok, JL; Melet, A; Miller, K; Ren, R; Rodin, HY; Santos, T; Song, K; Wu, C; Yeckes-Rodin, H | 1 |
Chen, SM; Cui, XY; Han, XF; Ling, Z; Shao, M; Sun, L; Wang, F; Zhang, H | 1 |
Budunova, IV; Kirsanov, KI; Lesovaya, EA; Yakubovskaya, MG; Yemelyanov, AY | 1 |
Gong, Y; Shan, Q; Yang, X; Zheng, B; Zhou, R | 1 |
Chen, SJ; Chen, YL; Chen, Z; Cheng, X; Fang, HT; Feng, TT; Gao, L; Hu, ZG; Liu, Z; Ma, L; Pan, XF; Sheng, GQ; Xie, J; Yang, Y; Yu, XJ; Zhang, B; Zhang, FX; Zhao, HX; Zhen, T; Zhou, GB | 1 |
Kim, WS; Lee, SJ; Park, C; Yeom, SY | 1 |
Chen, KF; Chen, MH; Huang, HP; Kuo, HY; Liu, CY; Shiau, CW; Tzeng, CH | 1 |
Arzeni, D; Astolfi, D; Catavitello, C; D'Antonio, D; Farina, C; Favaro, M; Fazii, P; Fontana, C; Hendrickx, M; Masciarelli, G; Pitzurra, L; Polilli, E; Savini, V; Sisti, M; Stubbe, D | 1 |
Chen, WM; Chen, ZZ; Shang, J; Wei, TN; Wu, WB | 1 |
Kato, M; Kimura, H; Kobayashi, Y; Kozawa, K; Kuroiwa, M; Minakami, H; Morikawa, A; Oshima, S | 1 |
Dent, P; Grant, S; Rahmani, M; Yu, C | 1 |
Berg, SL; Blaney, SM; D'Argenio, DZ; Gannavarapu, A; Horton, TM; Plon, SE | 1 |
Furukawa, Y; Ishii, H; Kano, Y; Kobayashi, Y; Ozawa, K; Sutheesophon, K; Takatoku, MA | 1 |
Jaehde, U; Scheulen, ME; Simons, S | 1 |
Cloos, J; Kaspers, GJ; Vink, J | 1 |
Beck, A; Berkers, CR; Burg, D; Driessen, C; Gogel, J; Kammer, W; Kraus, M; Ovaa, H; Overkleeft, H; Reich, M; Rückrich, T | 1 |
Adamson, PC; Blaney, SM; Bomgaars, LR; Brockman, AH; Horton, TM; Ingle, AM; Pati, D; Paton, M; Plon, SE; Thompson, PA; Wright, J | 1 |
Chen, GQ; Li, D; Liu, W; Wang, Y; Wang, YC; Wu, YL; Yan, H | 1 |
Lü, SQ; Wang, JM; Yang, JM | 1 |
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX | 1 |
Ames, E; Barao, I; Hallett, WH; Hudig, D; Motarjemi, M; Murphy, WJ; Sayers, TJ; Shanker, A; Tamang, DL | 1 |
Irvine, AE; McCloskey, SM; McMullin, MF; Walker, B | 1 |
8 review(s) available for pyrazines and Leukemia
Article | Year |
---|---|
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; HMGB1 Protein; Humans; Hydroxychloroquine; Leukemia; Leukocytes; Lysosomes; Phagosomes; Pyrazines; Sirolimus | 2015 |
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Hematologic Neoplasms; Humans; Leukemia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lactones; Leukemia; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles | 2009 |
[Bortezomib].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
Proteasome inhibition as novel treatment strategy in leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase I as Topic; Forecasting; Humans; Leukemia; NF-kappa B; Protease Inhibitors; Pyrazines; Ubiquitin | 2006 |
[Effects of proteasome inhibitors on leukemias].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Leukemia; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
The therapeutic potential of the proteasome in leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Gene Expression Regulation, Leukemic; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Biological; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2008 |
1 trial(s) available for pyrazines and Leukemia
Article | Year |
---|---|
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Humans; I-kappa B Kinase; Immunoblotting; Infant; Leukemia; Male; Maximum Tolerated Dose; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
29 other study(ies) available for pyrazines and Leukemia
Article | Year |
---|---|
Selective Chemical Activation of Piezo1 in Leukemia Cell Membrane: Single Channel Analysis.
Topics: Cell Membrane; Humans; Ion Channels; Leukemia; Mechanotransduction, Cellular; Pyrazines; Single-Cell Analysis; Thiadiazoles | 2021 |
Novel (S)-1,3,4,12a-tetrahydropyrazino[2,1-c][1,4]benzodiazepine-6,12(2H,11H)-dione derivatives: Selective inhibition of MV-4-11 biphenotypic B myelomonocytic leukemia cells' growth is accompanied by reactive oxygen species overproduction and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia; Mice; Pyrazines; Reactive Oxygen Species; S Phase Cell Cycle Checkpoints; Stereoisomerism; Structure-Activity Relationship | 2018 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Glucocorticoids; Humans; Hydrocortisone; Jurkat Cells; Leukemia; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA, Messenger | 2013 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Disease Progression; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Middle Aged; NF-kappa B; Phenotype; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Topics: Actinobacteria; Boronic Acids; Bortezomib; Catalysis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia; Mutation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Up-Regulation | 2014 |
Differential impact of bortezomib on HL-60 and K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Leukemic; Heat-Shock Proteins; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Pyrazines; Time Factors | 2015 |
[Study on effect of tetramethylpyrazine on proliferation and apoptosis of leukemic U937 cells and its mechanism].
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 2; Humans; Leukemia; Proto-Oncogene Proteins c-bcl-2; Pyrazines; U937 Cells | 2015 |
Proteasome inhibitors in pediatric cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Child; Humans; Leukemia; Neoplasms; Protease Inhibitors; Pyrazines | 2008 |
BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Gene Silencing; Humans; Leukemia; Mice; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering | 2009 |
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Chymotrypsin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; K562 Cells; Leukemia; Pyrazines | 2010 |
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Nude; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Remission Induction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
[Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and XIAP expression in K562 cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; K562 Cells; Leukemia; Pyrazines; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.
Topics: Acetates; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytostatic Agents; Fluocinolone Acetonide; Humans; K562 Cells; Leukemia; Ligands; NF-kappa B; Pyrazines; Receptors, Glucocorticoid; Tacrolimus Binding Proteins; Transcription Factor AP-1; Tyramine | 2011 |
Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2012 |
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Humans; Leukemia; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-kit; Pyrazines; Translocation, Genetic | 2012 |
Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Jurkat Cells; K562 Cells; Leukemia; Lymphoma; Mitochondria; Pyrazines; ras Proteins; RNA, Small Interfering; Up-Regulation | 2012 |
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Replication; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Membrane Proteins; Mice; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription, Genetic; Xenograft Model Antitumor Assays | 2013 |
An atypical, pigment-producing Metschnikowia strain from a leukaemia patient.
Topics: Amphotericin B; Antifungal Agents; Base Sequence; DNA, Fungal; DNA, Ribosomal; Fluconazole; Humans; Italy; Leukemia; Male; Metschnikowia; Microbial Sensitivity Tests; Molecular Sequence Data; Mycoses; Phylogeny; Pigments, Biological; Pyrazines; Sequence Analysis, DNA; Sputum; Voriconazole | 2013 |
[Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
Topics: Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia; NF-kappa B; Pyrazines; RNA, Messenger | 2012 |
Superoxide radical generation and Mn- and Cu-Zn superoxide dismutases activities in human leukemic cells.
Topics: Adult; Anions; Child; Humans; Imidazoles; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocytes; Manganese; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Oxidative Stress; Oxygen; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Sodium Dodecyl Sulfate; Superoxide Dismutase; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2003 |
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cytochromes c; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Models, Biological; Protease Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species; Signal Transduction; U937 Cells | 2004 |
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Drug Interactions; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Infant; Inhibitory Concentration 50; Leukemia; Male; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured | 2006 |
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Topics: 14-3-3 Proteins; Antibiotics, Antineoplastic; Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 9; Caspase Inhibitors; Caspases; Cytochromes c; Depsipeptides; DNA-Binding Proteins; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HL-60 Cells; Humans; K562 Cells; Ku Autoantigen; Leukemia; Mitochondria; Mitochondrial Membranes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines | 2006 |
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Leukemia; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Protease Inhibitors; Protein Kinase C-delta; Pyrazines; Tumor Cells, Cultured | 2007 |
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytotoxicity, Immunologic; Fas Ligand Protein; Immunotherapy; Killer Cells, Natural; Leukemia; Mice; Mice, Inbred Strains; Neoplasms; Perforin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2008 |